Expertise in
21
conditions

Dr. Marlise R. Luskin

Hematology
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 
Accepting New Patients
Offers Telehealth
15 Years of Experience
Expertise in
21
conditions
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 

Overview

Marlise Luskin is a Hematologist practicing medicine in Boston, Massachusetts. She has been practicing medicine for over 15 years.

Dr. Luskin is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 160 peer reviewed articles and participating in 10 clinical trials. Dr. Luskin is currently accepting new patients.

Specialties

Hematology

Licenses

Student in an Organized Health Care Education/Training Program in MA

Hospital Affiliations

Newton-Wellesley Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Brigham And Women's Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2026
Intervention Type: Biological, Procedure
Study Drugs: Blinatumomab, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
Enrollment Status: Terminated
Publish Date: February 27, 2026
Intervention Type: Drug
Study Drug: MBG453
Study Phase: Phase 2
A Phase 1 Study of Venetoclax in Combination With Inotuzumab Ozogamicin for B-cell Acute Lymphoblastic Leukemia (B-ALL)
A Phase 1 Study of Venetoclax in Combination With Inotuzumab Ozogamicin for B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Venetoclax, Dexamethasone, Inotuzumab Ozogamicin
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: MBG453, Hypomethylating agents
Study Phase: Phase 2
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: Sabatolimab, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Enrollment Status: Terminated
Publish Date: July 22, 2024
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drug: Midostaurin
Study Phase: Phase 3
View 8 Less Clinical Trials

160 Total Publications

Blinatumomab administration in the outpatient setting: Safety and health care utilization.
Blinatumomab administration in the outpatient setting: Safety and health care utilization.
Journal: Cancer
Published: May 01, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Cutler is a Hematologist practicing medicine in Boston, Massachusetts. Dr. Cutler is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. Cutler is currently accepting new patients.

Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Matthew Heeney is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Heeney is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy. Dr. Heeney is currently accepting new patients.

Frequently Asked Questions about Dr. Marlise R. Luskin

How do I make an appointment with Dr. Marlise R. Luskin?

You can book an appointment with Dr. Marlise R. Luskin by calling their office at 877-442-3324. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marlise R. Luskin a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marlise R. Luskin is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marlise R. Luskin specialize in?

While Dr. Marlise R. Luskin is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Marlise R. Luskin participate in research or clinical trials?

Yes. Dr. Marlise R. Luskin has published 160 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Marlise R. Luskin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marlise R. Luskin accept my insurance?

Dr. Marlise R. Luskin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 877-442-3324 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Luskin's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 9 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile